TRUVESIC Trademark

Trademark Overview


On Tuesday, May 16, 2023, a trademark application was filed for TRUVESIC with the United States Patent and Trademark Office. The USPTO has given the TRUVESIC trademark a serial number of 97939159. The federal status of this trademark filing is FIRST EXTENSION - GRANTED as of Wednesday, June 12, 2024. This trademark is owned by CG Oncology, Inc.. The TRUVESIC trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical products for the treatment of cancer, pharmaceutical preparations and biological preparations for the treatment of cancer and immunological disorders; Biopharmaceuticals for the treatment of cancer, namely, antibodies, non-antibody proteins, blood and blood components, stem cells, hormones, blood factors, tumor necrosis factors; Chemical preparations for medical or pharmaceutical purposes, namely, for cancer treatment, oncology and immunotherapy for auto immune diseases; Pharmaceutical products, namely, diagnostic kits consisting primarily of monoclonal antibodies, buffers, and reagents for use in disease testing
truvesic

General Information


Serial Number97939159
Word MarkTRUVESIC
Filing DateTuesday, May 16, 2023
Status730 - FIRST EXTENSION - GRANTED
Status DateWednesday, June 12, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, April 9, 2024

Trademark Statements


Goods and ServicesPharmaceutical products for the treatment of cancer, pharmaceutical preparations and biological preparations for the treatment of cancer and immunological disorders; Biopharmaceuticals for the treatment of cancer, namely, antibodies, non-antibody proteins, blood and blood components, stem cells, hormones, blood factors, tumor necrosis factors; Chemical preparations for medical or pharmaceutical purposes, namely, for cancer treatment, oncology and immunotherapy for auto immune diseases; Pharmaceutical products, namely, diagnostic kits consisting primarily of monoclonal antibodies, buffers, and reagents for use in disease testing

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateThursday, June 15, 2023
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameCG Oncology, Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressIrvine, CA 92618

Party NameCG Oncology, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressIrvine, CA 92618

Trademark Events


Event DateEvent Description
Friday, May 19, 2023NEW APPLICATION ENTERED
Thursday, February 8, 2024ASSIGNED TO EXAMINER
Thursday, June 15, 2023NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Wednesday, February 14, 2024NON-FINAL ACTION E-MAILED
Wednesday, February 14, 2024NON-FINAL ACTION WRITTEN
Wednesday, February 14, 2024NOTIFICATION OF NON-FINAL ACTION E-MAILED
Monday, March 4, 2024APPROVED FOR PUB - PRINCIPAL REGISTER
Friday, February 16, 2024CORRESPONDENCE RECEIVED IN LAW OFFICE
Friday, February 16, 2024TEAS/EMAIL CORRESPONDENCE ENTERED
Friday, February 16, 2024TEAS RESPONSE TO OFFICE ACTION RECEIVED
Tuesday, April 9, 2024PUBLISHED FOR OPPOSITION
Wednesday, March 20, 2024NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, April 9, 2024OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, June 4, 2024NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Wednesday, June 12, 2024SOU TEAS EXTENSION RECEIVED
Wednesday, June 12, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, June 12, 2024SOU EXTENSION 1 GRANTED
Wednesday, June 12, 2024SOU EXTENSION 1 FILED